Heat Shock Protein 90 as a Therapeutic Target in Lung Cancer: Rationale and Current Progress
A CME-certified satellite lunch symposium held adjunct to the 14th Annual International Lung Cancer Congress®
Participants must be registered for main International Lung Cancer Congress® to attend this lunch symposium.
Saturday, July 27, 2013 ● 11:45 am – 1:00 pm
The satellite symposium will feature a panel of experts in lung cancer medical oncology. Participants will learn from engaging presentations delivered by the thought leaders and by reviewing and discussing recent practice changing data, realistic and complex scenarios, sharing clinical experiences, and clarifying best practices.
This CME-certified activity is directed toward all attendees of the ILCC Congress, which includes medical oncologists, thoracic surgeons, pathologists, pulmonologists, and interventional radiologists who treat patients with lung cancer.
Increase awareness of new data regarding heat shock protein 90 as a therapeutic target to treat patients with NSCLC
Evaluate the clinical data presented about new agents in development for lung cancer and determine which of patients may be appropriate candidates for clinical trial enrollment
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT
David R. Gandara, MD
Laurie Gaspar, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Professor and Chair
Department of Radiation Oncology
Grohne Chair in Clinical Oncology
University of Colorado School of Medicine
Introduction: HSP90 as a Target in Cancer Therapy
Current Progress in Therapeutic Application of HSP90 Inhibition
Potential for Integration of HSP90 inhibition into Radiotherapy
Continuing Education Information for This Activity
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maxmium of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from Synta Pharmaceuticals.